What is Xeris Biopharma Holdings Inc Annual Revenue?

Xeris Biopharma Holdings Inc Annual Revenue rose 23.89%, in the last year to $203.07 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

What is Xeris Biopharma Holdings Inc Annual Net Profit?

Xeris Biopharma Holdings Inc Annual Net Profit rose 11.92% in the last year to $54.84 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

What is Xeris Biopharma Holdings Inc Price to Earning Ratio?

Xeris Biopharma Holdings Inc Price to Earning Ratio is -16.48, which is negative.

What is Xeris Biopharma Holdings Inc Stock Price?

Xeris Biopharma Holdings Inc Stock Price rose 179.52% and outperformed its sector by 169.62% in the past year.

What is Xeris Biopharma Holdings Inc Quarterly Revenue?

Xeris Biopharma Holdings Inc Quarterly Revenue rose 35.39% YoY to $60.1 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

What is Xeris Biopharma Holdings Inc Quarterly Net profit?

Xeris Biopharma Holdings Inc Quarterly Net profit rose 61.81% YoY to $5.11 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

What is Xeris Biopharma Holdings Inc Mutual Fund Holding?

Xeris Biopharma Holdings Inc Mutual Fund Holding increased by 0.16% in the last quarter to 24.38.

What is Xeris Biopharma Holdings Inc Promoter Share Holding?

Xeris Biopharma Holdings Inc Promoter Share Holding increased by 3.14% in the most recent quarter to 35.18%.

What is Xeris Biopharma Holdings Inc Institutional Holding?

Xeris Biopharma Holdings Inc Institutional Holding decreased by 0.32% in the last quarter to 42.23.

How is the Xeris Biopharma Holdings Inc today?

The Xeris Biopharma Holdings Inc today is trading in the green, up by 1.03% at 5.87.

How has Xeris Biopharma Holdings Inc performed historically?

The Xeris Biopharma Holdings Inc is currently trading up 1.03% on an intraday basis in the past week the index rose 21.78%. The index has been up 71.64% in the past quarter and rose 179.52% in the past year. You can view this in the overview section.

Xeris Biopharma Holdings Inc XNAS: XERS

Xeris Biopharma Holdings Inc Live Share Price Today, Share Analysis and Chart

Name: Xeris Biopharma Holdings Inc: Is Infosys Ltd. worth buying?
Item: Xeris Biopharma Holdings Inc
Rating: 2.14241675
Author: Trendlyne DVM scores

Download real time

5.87 0.06 (1.03%)

New 52W High today

3.5M XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Xeris Biopharma Holdings Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	903.6
PE TTM Negative PE TTM Unavailable in chosen country	-16.5
PEG TTM Negative PEG TTM Unavailable in chosen country	-1.4
Price to Book Negative Price to Book Unavailable in chosen country	-31.9
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	42.2
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	35.4
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	23.9
Net Profit Qtr Growth YoY % High in industry Unavailable in chosen country	61.8
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	11.9
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-16.6
Piotroski Score High in industry Unavailable in chosen country	3
Rel Perf vs Sector quarter% Unavailable in chosen country	64.4

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

9.2 / 100

Technically Bullish

76.5 / 100

1Yr Price target upside is 6%

6 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Xeris Biopharma Holdings Inc Stock Price Analysis

Day Price Range 1.0% 1 Day return Unavailable in chosen country	5.9 (LTP) 5.66 LowHigh
Week Price Range 21.8% 1 Week return Unavailable in chosen country	5.9 (LTP) 4.86 LowHigh
Month Price Range 56.5% 1 Month return Unavailable in chosen country	5.9 (LTP) 3.66 LowHigh
52 Week Price Range 179.5% 1 Year return Unavailable in chosen country	5.9 (LTP) 1.76 LowHigh

View full Share Price History

Xeris Biopharma Holdings Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Xeris Biopharma Holdings Inc's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-0.4

Avg. Estimate

-0.1

Low Estimate

-0.2

High Estimate

0.1

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 78.4% in FY25

Consensus Recommendation

6 ANALYST Recommendations

BUY

The consensus recommendation from 6 analysts for Xeris Biopharma Holdings Inc is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Xeris Biopharma Holdings Inc Stock Analysis

Xeris Biopharma Holdings Inc stock analysis with key metrics, changes, and trends.

Xeris Biopharma Holdings Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$203.07 M	23.89%	positive	Annual Revenue rose 23.89%, in the last year to $203.07 M. Its sector's average revenue growth for the last fiscal year was 7.46%.
Annual Net Profit	$54.84 M	11.92%	positive	Annual Net Profit rose 11.92% in the last year to $54.84 M. Its sector's average net profit growth for the last fiscal year was -32.46%.
Price to Earning Ratio	-16.48	-	negative	Price to Earning Ratio is -16.48, which is negative.
Stock Price	$5.87	179.52%	positive	Stock Price rose 179.52% and outperformed its sector by 169.62% in the past year.
Quarterly Revenue	$60.1 M	35.39%	positive	Quarterly Revenue rose 35.39% YoY to $60.1 M. Its sector's average revenue growth YoY for the quarter was 5.96%.
Quarterly Net profit	$5.11 M	61.81%	positive	Quarterly Net profit rose 61.81% YoY to $5.11 M. Its sector's average net profit growth YoY for the quarter was -47.25%.
Mutual Fund Holding	24.38 %	0.16%	positive	Mutual Fund Holding increased by 0.16% in the last quarter to 24.38.
Promoter Share Holding	35.18 %	3.14%	positive	Promoter Share Holding increased by 3.14% in the most recent quarter to 35.18%.
Institutional Holding	42.23 %	-0.32%	negative	Institutional Holding decreased by 0.32% in the last quarter to 42.23.

VIEW LESS

Loading data..

Xeris Biopharma Holdings Inc - Company Profile

What does Xeris Biopharma Holdings Inc do?

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings Inc Management structure

All Gross Remunerations are in USD

Dr. Ken Johnson

Senior Vice President, Global Development and Medical Affairs

2025

Gross Remuneration

Year

Dr. Anh Nguyen, M.D.

Chief Medical Officer

2025

Gross Remuneration

2024

Gross Remuneration

Year

Xeris Biopharma Holdings Inc Live Share Price Today, Share Analysis and Chart

New 52W High today

Xeris Biopharma Holdings Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Xeris Biopharma Holdings Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Xeris Biopharma Holdings Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Xeris Biopharma Holdings Inc's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to grow by 78.4% in FY25

Consensus Recommendation

The consensus recommendation from 6 analysts for Xeris Biopharma Holdings Inc is BUY

Xeris Biopharma Holdings Inc Stock Analysis

Xeris Biopharma Holdings Inc stock analysis with key metrics, changes, and trends.

Annual Revenue rose 23.89%, in the last year to $203.07 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit rose 11.92% in the last year to $54.84 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio is -16.48, which is negative.

Stock Price rose 179.52% and outperformed its sector by 169.62% in the past year.

Quarterly Revenue rose 35.39% YoY to $60.1 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit rose 61.81% YoY to $5.11 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Mutual Fund Holding increased by 0.16% in the last quarter to 24.38.

Promoter Share Holding increased by 3.14% in the most recent quarter to 35.18%.

Institutional Holding decreased by 0.32% in the last quarter to 42.23.

Xeris Biopharma Holdings Inc - Company Profile

What does Xeris Biopharma Holdings Inc do?

Xeris Biopharma Holdings Inc Management structure

Dr. Ken Johnson

Senior Vice President, Global Development and Medical Affairs

Dr. Anh Nguyen, M.D.

Chief Medical Officer

Xeris Biopharma Holdings Inc Board of directors

Mr. Paul R. Edick

Chairman of the Board and Chief Executive Officer

Mr. John P. Shannon

Director and Chief Executive Officer

Dr. Jeffrey W. Sherman, F.A.C.P.,M.D.

Independent Director

Mr. John H. Johnson

Independent Director

Ms. Marla S. Persky

Chairperson of the Board

Mr. John P. Schmid

Lead Independent Director

Xeris Biopharma Holdings Inc FAQ

How is Xeris Biopharma Holdings Inc today?

Xeris Biopharma Holdings Inc today is trading in the green, and is up by 1.03% at 5.87.

How has Xeris Biopharma Holdings Inc performed historically?

Xeris Biopharma Holdings Inc is currently trading up 1.03% on an intraday basis. In the past week the stock rose 21.78%. stock has been up 71.64% in the past quarter and rose 179.52% in the past year. You can view this in the overview section.